Serbia could develop a larger role in Southeast Europe’s clinical-trials market by combining its medical institutions, specialist expertise, patient population and BIO4 ecosystem with competitive research costs. Clinical research has several characteristics that align with capabilities already present in the country, including university hospitals, specialist physicians, a sizeable population and lower operating costs than Western Europe. The sector also fits into Serbia’s expanding life-sciences policy agenda and could generate export revenues through specialised research services.
Unlike commodity industries and low-cost manufacturing, clinical-trial activity is based on professional and scientific services. Pharmaceutical and biotechnology companies pay for activities including patient recruitment, medical procedures, laboratory services, monitoring, data management and regulatory compliance.
Research spending creates demand across medical services
Contract research organisations can coordinate clinical-trial activity across multiple sites, generating demand for clinical coordinators, statisticians, pharmacists, nurses, laboratories and digital systems. The economic impact can therefore extend beyond individual hospitals. Each trial requires a network of specialised professional services, allowing research spending to circulate across a broader medical and scientific ecosystem.
Regulatory and operational efficiency could become an important competitive factor. In drug development, reducing the time required to recruit patients can have greater commercial value than differences in hospital fees between countries. For Serbia, this makes predictable ethics approvals, standardised contracts, clear data-protection rules and defined responsibilities between sponsors and public hospitals important components of the clinical-research framework.
BIO4 could connect research with hospitals
The BIO4 ecosystem could strengthen Serbia’s clinical-research proposition if it is closely integrated with hospitals rather than operating independently as a scientific centre. Clinical research increasingly incorporates areas such as biomarker research, genomics, biobanking and advanced diagnostics alongside conventional clinical trials. Connecting these capabilities with established medical centres could allow sponsors to recruit patients through hospitals while conducting specialised laboratory work within Serbia’s research infrastructure. Such integration would combine patient access with scientific and laboratory capabilities, creating a broader service offering for pharmaceutical and biotechnology companies.
Clinical research requires strong regulatory standards
The development of the sector also depends on maintaining confidence in research standards. Clinical trials require informed consent, effective oversight and transparent governance, making regulatory credibility central to Serbia’s ability to attract international research activity. Cost competitiveness would need to come from efficient procedures rather than weaker safeguards. Any perception that Serbia’s attractiveness resulted from lower clinical or regulatory standards would undermine the credibility of the market. If Serbia can combine efficient processes with strong research governance, international clinical-trial spending could increasingly reach Serbian hospitals and scientific institutions, creating an export-oriented service sector that uses domestic medical and scientific expertise without requiring that expertise to move abroad.
